According to Aurobindo Pharma
's latest financial reports the company has HK$7.79 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2024-03-31 | HK$5.93 B | -0.24% |
2023-03-31 | HK$5.95 B | 26.38% |
2022-03-31 | HK$4.70 B | -20.87% |
2021-03-31 | HK$5.95 B | 104.22% |
2020-03-31 | HK$2.91 B | 33.63% |
2019-03-31 | HK$2.18 B | 45.53% |
2018-03-31 | HK$1.49 B | 144.03% |
2017-03-31 | HK$0.61 B | -34.23% |
2016-03-31 | HK$0.93 B | 61.01% |
2015-03-31 | HK$0.57 B | 151.65% |
2014-03-31 | HK$0.23 B | -22.72% |
2013-03-31 | HK$0.29 B | 119.37% |
2012-03-31 | HK$0.13 B | -58.15% |
2011-03-31 | HK$0.32 B | 157.2% |
2010-03-31 | HK$0.12 B | -35.19% |
2009-03-31 | HK$0.19 B | -64.66% |
2008-03-31 | HK$0.55 B | -47.71% |
2007-03-31 | HK$1.05 B | 198.27% |
2006-03-31 | HK$0.35 B | 232.73% |
2005-03-31 | HK$0.10 B | -5.09% |
2004-03-31 | HK$0.11 B |